Performance Analysis of Beximco Pharmaceuticals Ltd.

Only available on StudyMode
  • Download(s) : 355
  • Published : July 19, 2011
Open Document
Text Preview
Royal Roads University, Canada
Dhaka Study Centre


Course Name: BUSA 530 Corporate Finance

Submitted to:
Mr. Mokdum Morshed

Title of the Assignment:


Submitted By:
Md. Fazlul Haque

Executive Summary

This report prepared to make a through analysis of the financial statements of Beximco Pharmaceuticals Ltd (BPL). The report mainly highlights the results of various ratio analysis of the company. In order to make the analysis more informative, inter-firm comparisons have also been provided by performing ratio analysis of other leading pharmaceutical companies in Bangladesh. It is hoped that the report would provide a reliable & effective insight into the performance of the particular company.

Beximco Pharmaceuticals Ltd. is a leading edge pharmaceutical company and is a member of the BEXIMCO Group, the largest private sector industrial conglomerate in Bangladesh. The company’s strategic strengths include strong recognition of its brands, highly skilled work force and diversified business mix. BPL started its operation in 1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of USA and now have grown to become nation's one of the leading pharmaceutical companies, supplying more than 10% of country's total medicine need. Today Beximco Pharma manufactures and markets its own `branded generics' for almost all diseases from AIDS to cancer, from infection to asthma, from hypertension to diabetes for both national and international markets.

Beximco Pharmaceuticals Ltd. Manufacture in several world-class manufacturing plants, ensuring high quality standards complying with the World Health Organization (WHO) approved current Good Manufacturing Practices (cGMP). BPL also contract manufacture for major international brands of leading multinational companies.

The recipient of three times `gold' national export trophy, Beximco Pharma is the largest exporter of pharmaceuticals from Bangladesh, Beximco Pharma is the only pharmaceutical company in Bangladesh received this highest national accolade for export, for record three times. BPL markets its own brands through its own professional sales and marketing teams in African, South Asian and other markets. Beximco Pharma is also supply its products to renowned hospitals and institutions in many countries.

Beximco Pharmaceuticals Ltd. have a strong market focus and are anticipating continued future growth by leveraging business capabilities and developing superior product brands and markets. In particular BPL is very interested in developing a strong export market in USA and Europe. To meet the future demand BPL have invested over US 50 million dollar to build a new state-of-the-art manufacturing plant, confirming to USFDA and UK MHRA standards. This new plant will also offer contract-manufacturing facility to leading pharmaceutical companies, especially from Europe and US.

Page 2

Table of Contents

Topic Page

Executive Summary 02

Chapter I-The Organization part

1. Introduction 05-06
1.1 Origin of the report
1.2 Objectives & goals
1.3 Methodology
1.4 Scopes & Limitations

2. Company Profile 07 -11
2.1 Company Background
2.2 Timeline of the Company
2.3 Corporate Strategies

Chapter II- The Project Part

3. Financial Statement Analysis 13

4. Performance Analysis 14-23
4.1 Comparative Analysis
4.2 Percentage Analysis
4.3 Ratio Analysis
4.4 The Ratios at a Glance

5. Company Overview 24

6. Pharmaceutical Industry Analysis of Bangladesh 25-27

7. Assessment of Financial Statement Analysis 28-30

8. Recommendations 31

9. Conclusion 32

10. References 33

Appendix A: For Ratio Calculation:
Balance Sheet- Beximco Pharmaceuticals Ltd.
Profit and...
tracking img